Roper Technologies, Inc. — Q2 2016 Form 10-Q
Business context and period. The diversified technology company reported the quarter and six months ended June 30, 2016. Its businesses serve niche markets through software and engineered products, across Medical & Scientific Imaging, RF Technology, Industrial Technology, and Energy Systems & Controls. Figures below are unaudited; dollar amounts are in millions except per-share data.
Financial performance
| Metric | Q2 2016 | Q2 2015 | First half 2016 | First half 2015 |
|---|---|---|---|---|
| Revenue | $931.6 | $889.5 | $1,834.0 | $1,754.8 |
| Gross profit / margin | $567.5 / 60.9% | $533.9 / 60.0% | $1,127.0 / 61.5% | $1,052.1 / 60.0% |
| Operating income / margin | $253.1 / 27.2% | $252.0 / 28.3% | $498.1 / 27.2% | $498.9 / 28.4% |
| Net earnings / margin | $158.1 / 17.0% | $171.3 / 19.3% | $309.5 / 16.9% | $327.1 / 18.6% |
| Diluted EPS | $1.54 | $1.69 | $3.02 | $3.22 |
| Operating cash flow | $169.7 | $172.5 | $376.8 | $432.9 |
- Revenue mix and segments: Q2 revenue rose 4.7%, as acquisitions net of divestitures contributed 7% while organic growth was negative 2%. First-half revenue rose 4.5%; acquisitions/divestitures contributed 7.7%, organic growth was negative 2.5%, and foreign exchange reduced growth by 0.7%.
- Q2 segment revenue increased 13% in Medical & Scientific Imaging and 13% in RF Technology, but declined 4% in Industrial Technology and 15% in Energy Systems & Controls. The latter segments faced weakness in oil-and-gas-related markets; RF organic sales also reflected completion of prior-year toll and traffic service contracts.
- Cash flow and investment: First-half investing cash outflow was $293.2, including $275.0 for acquisitions; capital expenditures were $18.3. Financing cash outflow was $232.0, including $180.0 of net revolving-credit repayments and $60.4 of cash dividends. Cash declined $156.2 to $622.3.
- Debt and liquidity: Management reported total debt of $3.107 billion and net debt of $2.485 billion at June 30, versus $3.289 billion and $2.510 billion, respectively, at year-end. Net debt / total net capital was 30.9%, down from 32.1%. There were no borrowings under the $1.85 billion unsecured credit facility; the company reported covenant compliance. Foreign-subsidiary cash of $488 million was considered permanently reinvested because repatriation could incur additional taxes.
Material changes and notable items
- Despite higher revenue and gross margin, operating income was nearly flat in Q2 and slightly lower for the first half. Higher SG&A as a share of sales and higher interest expense contributed to weaker operating and net margins. Net interest expense increased to $26.9 in Q2 from $20.2, and to $54.3 for the first half from $40.0, reflecting higher average debt balances and rates.
- First-half operating cash flow fell 13%, primarily due to income-tax payments and prepayments, including tax related to the 2015 Abel Pumps sale, and timing-related receivables. The company used cash for three acquisitions totaling $283 million: CliniSys, PCI Medical, and GeneInsight, all assigned to Medical & Scientific Imaging. Purchase-price allocations were preliminary.
- The effective tax rate was 29.7% in Q2 and 30.0% for the first half, versus 25.6% and 28.4% a year earlier. The prior-year periods included a $15.9 tax benefit from resolution of a tax matter. Early adoption of stock-compensation accounting produced current-period tax benefits of $4.2 in Q2 and $5.5 for the first half, which may add tax-rate volatility.
- Foreign-currency translation reduced comprehensive income; the filing reports a $47 million pretax Q2 translation decrease and a $42 million decrease for the first half. A portion related to goodwill and was not expected to directly affect future cash flows.
- Q2 orders were $956 million, up from $881 million, and backlog was $1.137 billion, up 8% year over year. Dividends declared were $0.30 per share in Q2, compared with $0.25.
Outlook, risks, and contingencies
- Management expected an approximately 30% effective tax rate for 2016 and capital expenditures for the rest of the year to be comparable to prior years as a percentage of sales. It expected operating cash generation to support operations and debt reduction, but said the pace would depend on acquisitions and business performance. No specific earnings or revenue guidance was provided in the supplied filing text.
- Management cited geopolitical and economic uncertainty and identified risks including acquisition integration and liabilities, indebtedness and interest rates, foreign exchange, cyclical markets, customer concentration, competition, product liability and warranty claims, asbestos litigation, regulation, and potential goodwill or intangible-asset impairment.
- Ordinary-course legal matters included product-liability, employment, and asbestos-related claims. Management believed recorded provisions and insurance were adequate for covered claims and did not expect the matters overall to materially affect financial position, results, or cash flows; potential asbestos liability could not be determined. Warranty accruals were $10.5 million at June 30.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the period.
Important facts for investors to verify
- Whether organic demand stabilizes, particularly in Energy Systems & Controls, Industrial Technology, and RF Technology, and how much future growth depends on acquisitions.
- Whether acquisition integration and returns support margins, cash generation, and further debt reduction.
- The drivers of lower operating and net margins despite improved gross margin, including SG&A, interest expense, and tax-rate changes.
- Cash-flow conversion after tax payments, acquisition spending, and working-capital movements; also assess the availability and tax implications of foreign-held cash.
- Developments in litigation, warranty exposure, foreign exchange, and the annual goodwill and indefinite-lived-intangible impairment review.